Table 1.

Observational studies of discontinuation of secondary prophylaxis against cytomegalovirus maintenance treatment in people with previous cytomegalovirus disease.

Ref	Criteria for discontinuation	Participants	Follow up (months)	Relapses
	CD4 greater than 70	17	14.5 (mean)	5
	CD4 75 or greater	8	8 (median)	0
	CD4 greater than 150	14	16.4 (mean)	0
	CD4 greater than 100	8	11.4 (mean)	0
*	CD4 183 (median)	11	5 (median)	0
	CD4 greater than 150 VL less than 200/mL –ve CMV by PCR	7	9 (median)	0
	CD4 greater than 75 VL less than 30,000/mL	48	11 (mean)	2
	CD4 greater than 100 VL less than 500 or CD4 greater than 150 VL less than 10,0000 copies/mL	36	21 (median)	1
	CD4 greater than 143	41	20.4 (mean)	0

Studies with more than 5 people are included. CD4 count is measured in cells/mm³. * McDonald et al is an early report of the same study followed by the Torriani et al report. All relapses in the latter report occurred in people who had already experienced a decrease of CD4 to less than 50/mm³. CMV, cytomegalovirus; PCR, polymerase chain reaction; Ref, reference; VL, viral load (HIV-1 RNA in plasma); –ve, negative.